Canaloplasty an option after failed trabeculectomy

Article

If initial trabeculectomy has failed, canaloplasty can be an option, according to Dr Brusini

A perfectly performed trabeculectomy can fail to lower intraocular pressure (IOP), even if mitomycin C has been used, because of pre-existing conjunctival scarring. If this is the case, a second trabeculectomy will seldom provide adequate IOP control for precisely the same reasons that caused the initial surgical failure. Typically, either the implant of a tube or a diode laser cyclophotocoagulation would be recommended as the next step for treating these cases, but both of these options entail several possible serious complications. Therefore, an alternative surgical option for treating glaucoma is essential.

Although it is normally indicated for eyes that have not undergone previous filtrating surgery for glaucoma, canaloplasty is a viable alternative surgical option for a select number of eyes in which postoperative gonioscopic examination shows that the initial 'trabeculectomy' had been performed anterior to the trabecular structures - in other words, had in fact been a sclero-keratectomy - and that Schlemm's canal had been left intact. This scenario is now seen more frequently, especially in eyes in which an emport-piece trabeculectomy is associated with a one-site phacoemulsification.

As canaloplasty is not dependent on conjunctiva status for proper functioning, it is an appropriate treatment in these eyes, particularly in cases where IOP remains elevated despite maximum tolerated medical therapy and therefore further surgery is indicated.

"A mandatory prerequisite for this surgery is an apparently intact Schlemm's canal at gonioscopy," he notes. "The presence of peripheral anterior synechiae or previous argon laser trabeculoplasty can affect the success of canaloplasty, making it difficult or sometimes impossible to perform cannulation; however, these should not be considered as absolute contraindications for this procedure."

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.